|15th September 2020||Scott B. Ullem||33,150||Open or private sale||$83.43||$2,765,747.59|
|15th September 2020||Scott B. Ullem||33,150||Exercise of derivative||$21.76||$721,344.00|
|14th September 2020||Scott B. Ullem||26,700||Exercise of derivative||$13.98||$373,266.00|
|14th September 2020||Scott B. Ullem||26,700||Open or private sale||$82.21||$2,194,908.21|
|11th September 2020||Huimin Wang||310||Open or private sale||$82.97||$25,720.39|
|11th September 2020||Huimin Wang||11,339||Open or private sale||$82.43||$934,625.01|
|11th September 2020||Huimin Wang||81||Open or private sale||$83.00||$6,723.00|
|11th September 2020||Donald E Jr Bobo||876||Open or private sale||$82.90||$72,623.99|
|11th September 2020||Donald E Jr Bobo||13,074||Exercise of derivative||$13.98||$182,774.52|
|11th September 2020||Huimin Wang||11,649||Exercise of derivative||$13.98||$162,853.02|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.